(NASDAQ: AARD) Aardvark Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.06%.
Aardvark Therapeutics's earnings in 2025 is N/A.On average, 4 Wall Street analysts forecast AARD's earnings for 2025 to be -$49,629,417, with the lowest AARD earnings forecast at -$63,786,005, and the highest AARD earnings forecast at -$34,062,594. On average, 4 Wall Street analysts forecast AARD's earnings for 2026 to be -$60,206,178, with the lowest AARD earnings forecast at -$72,464,373, and the highest AARD earnings forecast at -$50,985,412.
In 2027, AARD is forecast to generate -$63,135,127 in earnings, with the lowest earnings forecast at -$63,135,127 and the highest earnings forecast at -$63,135,127.